Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in areas such as immunooncology, immunology, fibrotic diseases, anti viral applications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. Combining technical capabilities with antisense drug discovery and development expertise, a global KOL network and the Company’s validated partnership model, Secarna feels enabled to write new chapters in the book of ASO discovery and development.

Über Secarna Pharmaceuticals GmbH & Co. KG:

Field of Activity Discovering, testing and selecting ASOs of the third generation for pre-clinical and clinical development in a variety of therapeutic indications.
Partners Secarna’s objective is to form strategic partnerships leveraging the strengths of the Company and its partners to produce maximum value for the benefit of the alliances throughout their lifetimes. Secarna’s LNAplusTM platform and ASOs have been validated by inhouse projects as well as in academic and industry collaborations.
Unique Selling Point Secarna’s proprietary, customized, in-house drug discovery platform LNAplusTM encompasses all aspects of drug discovery and pre-clinical development, including a powerful proprietary bioinformatics modelling system, a best-in-class high throughput screening system, and bespoke target-specific functional assays. This results in highly specific, safe and efficacious antisense therapies for challenging or currently not druggable targets.
Date of Incorporation/Number of Employees 2015/15




Tel +49 89 215 46 375
Fax +49 6421 98300599


Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried